Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4199-88-6,5-Nitro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

Complex 1 was prepared by a conventional synthetic method, in which a mixture ofdichloromethane and methanol (42 mL, 2:1) was added to a flask containing [Ir(Hppy)2Cl]2 (0.323 g,0.30 mmol) and NP (0.135 g, 0.60 mmol) [19]. The mixture was refluxed for 6 h under argon to givea red brown solution. After cooling, a bright red precipitate was obtained by dropwise additionof concentrated NH4PF6 aqueous solution with stirring at room temperature for 2 h. The crudeproduct was purified by column chromatography on alumina eluted with dichloromethane-acetone(1:3, v/v). The red band was collected, the solvent was evaporated under the reduced pressure, and abrown-yellow powder was obtained. Yield: 86%. Anal. Calc for C34H23F6N5O2PIr: C, 46.90; H, 2.66;N, 8.04%. Found: C, 46.81; H, 2.72; N, 8.12%. 1H NMR (500 MHz, DMSO-d6): 9.46 (s, 1H), 9.20 (d, 1H,J = 8.0 Hz), 9.12 (d, 1H, J = 7.5 Hz), 8.34 (dd, 2H, J = 5.5, J = 6.0 Hz), 8.26 (d, 2H, J = 8.0 Hz), 8.19-8.15(m, 2H), 7.95 (d, 2H, J = 8.0 Hz), 7.88 (t, 2H, J = 7.5 Hz), 7.52 (dd, 2H, J = 6.0, J = 6.0 Hz), 7.06 (t, 2H,J = 7.5 Hz), 7.01-6.94 (m, 5H), 6.26 (d, 2H, J = 7.5 Hz). 13C NMR (125 Hz, DMSO-d6): 166.70, 153.41,151.88, 149.56, 149.11, 147.87, 146.79, 144.96, 144.04, 140.80, 138.87, 135.24, 131.23, 130.33, 128.52, 128.34,127.45, 125.14, 123.97, 123.89, 122.60, 120.03. ESI-MS (CH3CN): m/z 725.9 ([M-PF6]+)., 4199-88-6

As the paragraph descriping shows that 4199-88-6 is playing an increasingly important role.

Reference£º
Article; Zhang, Li-Xia; Gu, Yi-Ying; Wang, Yang-Jie; Bai, Lan; Du, Fan; Zhang, Wen-Yao; He, Miao; Liu, Yun-Jun; Chen, Yan-Zhong; Molecules; vol. 24; 17; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-95-9,4-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,14162-95-9

General procedure: In a tube were added 6-bromo-2,2-bipyridine (70.5mg, 0.3mmol, 1equiv.), phenothiazine (77.7mg, 1.3equiv.), RuPhos-Pd-G2 (23.4mg, 10mol%) and t-BuOK (50.5mg, 1.5equiv). The tube was sealed, purged three times with argon and 1mL of anhydrous dioxane was added. The reaction mixture was stirred at 110C for 18h. After cooling to room temperature, 10mL of H2O were added and the aqueous layer was extracted three times with ethyl acetate (3¡Á10 mL). The combined organic layers were dried with MgSO4 and the solvent was removed under reduced pressure. The residue was purified by silica gel flash chromatography (50/50: CH2Cl2/cyclohexane) affording 51.2 mg of L1 (0.145 mmol, 48%) as an amorphous pale yellow solid.

As the paragraph descriping shows that 14162-95-9 is playing an increasingly important role.

Reference£º
Article; Tabey, Alexis; Mendy, Jonathan; Hermange, Philippe; Fouquet, Eric; Tetrahedron Letters; vol. 58; 32; (2017); p. 3096 – 3100;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

103946-54-9, 4,4′-Dimethyl-2,2′-bipyridine (1.5 g, 8 mmol) and selenium dioxide (887.68 mg, 8 mmol) were refluxed in 100 ml of 1,4-dioxane for 24 hours, after cooling to room temperature, the black solid was filtered off and solvent was removed by evaporation to give a white solid. This solid was dissolved by stirring with 100 ml of ethyl acetate, the insoluble material was filtered off, and the filtrate was washed three times with 20 ml of a 1.0 M sodium carbonate solution. The organic phase was extracted three times with 50 ml of 0.3 M sodium metabisulfite solution, the aqueous phase was combined, the pH was adjusted to 10 with sodium carbonate solution, and extracted four times with 20 ml of chloroform, the organic phase was combined, which was dried over anhydrous sodium sulfate and solvent was removed by evaporation to give a crude product. The crude product was purified by column chromatography eluting with petroleum ether / ethyl acetate (1: 4) to give aldehyde-substituted bipyridine 398 mg was obtained in a yield of 25%. The aldehyde-substituted bipyridine was dissolved in 20 ml of ethanol, stirred with 4 ml of a silver nitrate aqueous solution, then 10 ml of a 1.0 M aqueous sodium hydroxide solution was slowly added and reacted at room temperature for 15 hours. The solvent was removed by evaporation and the solid was washed twice with 4 ml of 1.3 M sodium hydroxide and 4 ml of water, the combined filtrate was extracted three times with 10 ml of chloroform, aqueous phase pH was 3.5 with 4 M hydrochloric acid, the resulting white solid was filtered and dried in vacuo to give carboxy-substituted bipyridine 258 mg, yield 60%. The resulting carboxyl substituted bipyridine (1.3 mmol) was all dissolved in 20 ml DMF, then aminothiazole compound (300 mg, 1.3 mmol), 1-hydroxy-7-azobenzotriazole (1.3 mmol, 177 mg), 4-dimethylaminopyridine (1.3 mmol, 146 mg), 1-ethyl-carbonyldiimide hydrochloride (1.3 mmol, 87 mg) were added thereto, and stirred at room temperature for 6 hours. The obtained solid was filtered, washed four times with 25 ml of water and dried in vacuo to give the Aminothiazole functional group-substituted polypyridine ligand (L1) 457 mg, yield 82%. All the obtained L1 (1.06 mmol) and the compound cis-[Ru(bpy)2Cl2].2H2O (442 mg, 0.85 mmol) were refluxed under 20 ml of ethylene glycol and argon gas protection for 8 hours. After cooling to room temperature, 10 ml of a saturated aqueous solution of ammonium hexafluorophosphate was added,the obtained orange precipitate was filtered, washed once with 15 ml of water, washed three times with 30 ml of anhydrous diethyl ether and dried in vacuo to give crude product. The crude product is subjected to neutral alumina column chromatography, and the only orange component is eluted with acetonitrile to obtain the target polypyridyl ruthenium complex Ru1, amount 616 mg, yield 64%

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Yunnan University; Gao Feng; Yan Ru; Bi Xudan; (15 pag.)CN109232663; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,485-71-2

Example 11 (R)-1-(2-Hydroxyethyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid cinchonidine salt To cinchonidine (46.98 g (159.6 mmol)), ethyl acetate (1400 mL) was added, and while heating and stirring the resulting mixture under reflux (about 78 C.), (RS)-1-(2-hydroxyethyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid (50.00 g (159.6 mmol)) was added thereto. The resulting mixture was stirred for about 1 hour, and then gradually cooled to 20 to 30 C., and further stirred for about 1 hour at that temperature. The deposited crystal was filtered and washed with ethyl acetate (250 mL). The obtained wet crystal product was dried under reduced pressure at 40 C., whereby a crude product of the title compound (52.73 g) was obtained (yield: 54.4%). The diastereomeric excess of the obtained salt was 71.9% de. To the obtained crude product (50.00 g), ethanol (75 mL) and ethyl acetate (100 mL) were added, and the resulting mixture was heated and stirred under reflux (about 78 C.). After the mixture was stirred for about 1 hour, ethyl acetate (825 mL) was added thereto, and the resulting mixture was stirred under reflux again for about 0.5 hours. Thereafter, the mixture was cooled to 0 to 5 C. and stirred for about 1 hour at that temperature. The resulting crystal was filtered and washed with ethyl acetate (200 mL) cooled to 0 to 5 C. The obtained wet crystal product was dried under reduced pressure at 40 C., whereby the title compound was obtained (34.21 g, recovery rate: 68.4%, yield: 37.2%). The diastereomeric excess of the obtained salt was 98.7% de. 1H NMR (400 MHz, CDCl3) delta: 1.27-1.67 (m, 2H), 1.75-2.04 (m, 4H), 2.13-2.33 (m, 1H), 2.52-2.94 (m, 2H), 3.14-3.23 (m, 2H), 3.46-4.12 (m, 2H), 4.76-5.10 (m, 2H), 5.58-5.90 (m, 2H), 6.10-6.95 (m, 2H), 7.00-8.25 (m, 7H), 8.55-9.01 (m, 1H). MS (ESI): 313, 294

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; Watanabe, Masashi; Okachi, Takahiro; Kawahara, Michiaki; Nagasawa, Hiroshi; Sato, Noritada; Takita, Takashi; Hasegawa, Gen; (23 pag.)US2016/96803; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

14162-95-9, 4-Bromo-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

14162-95-9, A 100 mL reactor was dried by keeping it in an ovenovernight; it was closed with a rubber stopper and waspurged with argon for 20 min. In the reactor, Pd(PPh3)2Cl2,(44 mg, 0.063 mmol, 0.03 eq.) CuI (42 mg, 0.209 mmol,0.10 eq.) were added and the reactor was purged with argon.Compound 6 (0.720 g, 2.089 mmol, 1 eq.) was added as asolution in benzene (10 mL). Further benzene (20 mL) wasadded along with TEA (1.328 g, 0.726 mL, 13.128 mmol, 6eq.) and the solution was left to stir at rt under argon. The 4-bromo-2,2?-bipyridine, (0.540 g, 2.298 mmol, 1.10 eq.) DBU(3.82 g, 3.75 mL, 25.07 mmol, 12 eq.) and water (16 mg, 16mul, 0.875 mmol, 0.40 eq.) were finally added and the solutionwas put in a pre-heated oil bath 60C, and left to react undervigorous stirring for 18 h. The reaction was stopped and thebenzene was removed under vacuum by distillation. Theresidue was extracted with diethyl ether (3 ¡Á 50 mL) andwater (50 mL). The organic layer was washed with 10% HCl(3 ¡Á 50 mL) and brine (1 ¡Á 50 mL) and the organic phasewas dried with Na2SO4, filtered and evaporated under vacuum.The crude was purified by chromatography on Biotageon silica (100 g) with dichloromethane-TEA (0.5%) and afterwith a gradient from dichloromethane to dichloromethane:ethyl acetate 8:2. A yellow solid was finally obtained: 849.6mg (95%). m.p.: 153-156C. 1H NMR (200 MHz, CDCl3) delta 8.70 (m,2H, H6pyr and H6?pyr), 8.56 (s, 1H, H3pyr), 8.41 (d, J = 8.0Hz, 1H, H3?pyr), 7.83 (td, J = 7.8, 1.8 Hz, 1H, H4pyr), 7.51(dd, J = 3.7, 1.2 Hz, 1H, H3 or H3?), 7.44 (dd, J = 5.0, 1.5Hz, 1H, H5 or H5?), 7.37 (dd, J = 5.1, 1.1 Hz, 1H, H5 orH5?), 7.34-7.29 overlapping (m, J = 7.5 4.8, 1.1, 1H, H5pyror H5?pyr), 7.26 (dd, J = 5.1, 1.1 Hz, 1H, H3 or H3?), 7.20(m (dd + s), 3.5, 1.2 Hz, 2H, H4? and H5pyr or H5?pyr), 7.09(dd, J = 5.1, 3.7 Hz, 1H, H4 or H4?).7.06 (dd, J = 5.1, 3.7Hz, 1H, H4 or H4?). 13C NMR (50 MHz, CDCl3) delta 156.43(C2q-pyr), 155.65 (C2?q-pyr), 149.38 (C6-pyr or C6?-pyr),149.27 (C6-pyr or C6?-pyr), 139.97 (C3?th), 137.09 (C5?th),136.08 (C4?pyr), 135.54 (C2th), 134.64 (C2?th), 132.41(C4pyr), 128.10 (C4?th), 127.51 (C5th or C5?th), 127.07(C5th or C5?th), 126.40 (C3?pyr), 126.11 (C3?th), 125.35(C4th or C4?th), 125.16 (C4th or C?th), 124.53 (C3pyr),124.14 (C2th), 122.96 (C3th), 121.32 (C5pyr or C5?pyr),116.87 (C5pyr or C5?pyr), 91.77 (C?C), 89.69 (C?C). MS(EI, m/z): 426.09. Elemental analysis: required forC24H14N2S3, C 67.57, H 3.31, N 6.57, S 22.55, found: C67.60, H 3.28, N 6.62, S 22.50.

The synthetic route of 14162-95-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Quagliotto, Pierluigi; Prosperini, Simona; Viscardi, Guido; Letters in Organic Chemistry; vol. 14; 7; (2017); p. 472 – 478;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0,99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(5) Preparation of compound (6); To a compound (5) (0.13 g, 0.7 mmol) and KtOBu (0.2 g, 1.8 mmol), THF 20 mL was added, and the compound (3) (0.75 g, 1.8 mmol) was dissolved in 20 mL of THF and slowly added dropwise, and then the reaction mixture was agitated at 70 C for 12 hours. After the reaction, the solvent was removed and an organic layer was extracted with MC and separated by recrystallization.

99970-84-0 [2,2′-Bipyridine]-4,4′-dicarbaldehyde 4171663, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DONGJIN SEMICHEM CO., LTD.; WO2009/82163; (2009); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

153-94-6, H-D-Trp-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

C1. D-Tryptophan methyl ester; The title compound can be obtained by methylesterification of D-tryptophan in methanol with the aid of thionylchloride according to standard procedures., 153-94-6

153-94-6 H-D-Trp-OH 9060, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; ALTANA PHARMA AG; WO2006/79645; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1671-87-0,3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine,as a common compound, the synthetic route is as follows.

A 5¡Á10-6 M solution of compound 4 in 1:1 ethanol:H20 and a 5¡Á10-6 M solution of compound 12 in ethanol were prepared separately. 1 mL of each solution was added to a 3-mL UV cuvette, and the absorbance was measured every five minutes at room temperature for 40 minutes. Tetrazine 4 has an absorption maximum at 292 nm, and the product 13 has an absorption maximum at 312 nm. Also, product 13 displays significant absorption at 340 nm (e=12000), whereas tetrazine 4 displays minimal absorption (e=3000) at 340 nm. With monitoring at 292, 312 and 340 nm, the reaction was considered to be completed in 40 min

1671-87-0, 1671-87-0 3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine 315109, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; University of Delaware; US2009/23916; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.153-94-6,H-D-Trp-OH,as a common compound, the synthetic route is as follows.

Example 1 To a 1L three-necked flask was added 200mL of tetrahydrofuran, 20g D-tryptophan, 7.7g methylaminoacetonitrile, 38.2g EDC ¡¤ HCl and 1g 4-dimethylaminopyridine. The reaction was stirred at room temperature for 5 hours. After completion of the reaction, 300mL of ethyl acetate and 300mL water was added. The ethyl acetate layer was washed with 200mL saturated sodium chloride and stirred. Still stratification of the ethyl acetate layer was distilled under reduced pressure at 30C to a volume of about 200ml. The solution was recrystallized with 700ml of petroleum ether, filtered and vacuum dried at 40C to give 22.25g of compound III. HPLC purity 98%, Yield 91%., 153-94-6

153-94-6 H-D-Trp-OH 9060, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Zhejiang Yongning Pharmaceutical Co., Ltd.; Ye, Tianjian; Yuan, Youting; Chen, Xin; Zhang, Hongxun; (7 pag.)CN105348283; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of (S, S)-diphenylethylenediamine (250 mg, 1.2 mmol) and triethylamine (0.5 ml) in THF is added dropwise a solution of dansyl chloride (318 mg, 1.2 mmol) in THF (2 mi) at 0C. After stirring for 16 h at RT the solvent is removed in vacuum and the residue is resolved in methylenchloride (20 ml). The organic solution is washed with NaHCO3 solution (5 ml), dried over Na2SO4, and after filtration the solvent is removed. Flash chromatography affords (S, S)-5-dimethylamino-naphthalene-1-sulfonic acid (2-amino-1, 2-diphenyl-ethyl)- amide as yellow oil, which crystallizes by drying in vacuum. Molecular weight: 445. 59.’H- NMR (400 MHz, CDCI3) : 8.36 (t, J = 7.5 Hz, 2 H), 8.17 (dd, J = 7.2 Hz, 1.2 Hz, 1 H), 7.47 (dd, J = 8. 8 Hz, 1 H), 7.34 (dd, J = 8. 5 Hz, 1 H), 7.24-7. 16 (m, 4 H), 7.11 (d, J = 7. 5 Hz, 1 H), 6.99-6. 74 (m, 6 H), 4.61 (d, J = 8.5 Hz, 1 H), 4.20 (d, J = 8.5 Hz, 1 H), 2.80 (s, 6 H).

29841-69-8, As the paragraph descriping shows that 29841-69-8 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2005/92290; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI